Geode Capital Management
NRIX icon

Geode Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Geode Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.6M Buy
2,537,291
+17,062
+0.7% +$291K ﹤0.01% 1517
2026
Q1 		$39.1M Buy
2,520,229
+135,231
+6% +$2.24M ﹤0.01% 1630
2025
Q4 		$45.3M Buy
2,384,998
+502,316
+27% +$7.22M ﹤0.01% 1548
2025
Q3 		$17.4M Buy
1,882,682
+722
+0% +$7.5K ﹤0.01% 2068
2025
Q2 		$21.4M Buy
1,881,960
+157,592
+9% +$1.7M ﹤0.01% 1918
2025
Q1 		$20.5M Buy
1,724,368
+139,241
+9% +$2.33M ﹤0.01% 1886
2024
Q4 		$29.9M Buy
1,585,127
+137,087
+9% +$3.14M ﹤0.01% 1741
2024
Q3 		$32.5M Buy
1,448,040
+126,306
+10% +$2.86M ﹤0.01% 1706
2024
Q2 		$27.6M Buy
1,321,734
+221,399
+20% +$3.45M ﹤0.01% 1747
2024
Q1 		$16.2M Buy
1,100,335
+19,812
+2% +$213K ﹤0.01% 2046
2023
Q4 		$11.2M Buy
1,080,523
+35,238
+3% +$242K ﹤0.01% 2280
2023
Q3 		$8.22M Buy
1,045,285
+67,234
+7% +$614K ﹤0.01% 2381
2023
Q2 		$9.77M Buy
978,051
+47,360
+5% +$483K ﹤0.01% 2300
2023
Q1 		$8.26M Buy
930,691
+36,475
+4% +$380K ﹤0.01% 2378
2022
Q4 		$9.82M Buy
894,216
+77,754
+10% +$938K ﹤0.01% 2278
2022
Q3 		$10.6M Buy
816,462
+43,168
+6% +$683K ﹤0.01% 2203
2022
Q2 		$9.8M Buy
773,294
+120,800
+19% +$1.37M ﹤0.01% 2268
2022
Q1 		$9.14M Buy
652,494
+30,947
+5% +$549K ﹤0.01% 2412
2021
Q4 		$18M Sell
621,547
-9,151
-1% -$277K ﹤0.01% 2024
2021
Q3 		$18.9M Buy
630,698
+235,941
+60% +$7.28M ﹤0.01% 1998
2021
Q2 		$10.5M Buy
394,757
+71,237
+22% +$2.09M ﹤0.01% 2419
2021
Q1 		$10.1M Buy
323,520
+124,287
+62% +$4.7M ﹤0.01% 2361
2020
Q4 		$6.55M Buy
199,233
+15,331
+8% +$508K ﹤0.01% 2443
2020
Q3 		$6.42M Buy
+183,902
New +$4.63M ﹤0.01% 2249

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management's NRIX Position: Q2 2026 in Review

Geode Capital Management increased its Nurix Therapeutics (NRIX) stake by 0.68% in Q2 2026, buying an estimated $291K and bringing the position to 2,537,291 shares worth $61.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1517.

Geode Capital Management first reported a position in NRIX in Q3 2020 and has held it in 24 quarters since. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Geode Capital Management held 2,537,291 shares of Nurix Therapeutics worth $61.6M as of Q2 2026.
  • Geode Capital Management bought 17,062 Nurix Therapeutics shares in Q2 2026, an estimated $291K.
  • Nurix Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1517 holding.
  • Geode Capital Management first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.